New platelet function assays that accurately reflect platelet reactivity could change prevention strategies for arterial thrombosis, including acute myocardial infarction and stroke. Extracellular ADP secretion is a central hallmark of platelet activation and amplifies thrombotic responses. Existing bulk or population-level assays may obscure single-cell heterogeneity that could be clinically informative. The authors therefore developed a single-platelet approach to quantify extracellular ADP secretion within picolitre droplets.
The method, termed the Droplet ADP Secretion Assay (DASA), encapsulates individual platelets together with a fluorescent reporter for extracellular ADP inside picolitre-volume droplets using droplet microfluidics. This configuration permits isolation of single-platelet secretion events and real-time fluorescent detection of ADP release. The source reports that DASA robustly detected dose-dependent ADP secretion responses to agonists. Specific experimental parameters (for example droplet volume, reporter chemistry, flow rates, platelet preparation, number of platelets assessed, and statistical analysis) were not provided in the abstract and are therefore not reported here.
Using DASA, the investigators observed digital ADP secretion heterogeneity across single platelets: a major fraction of platelets produced detectable ADP secretion in response to agonists, while a remaining fraction did not respond. The assay demonstrated dose-dependent increases in ADP secretion with increasing agonist stimulus. These findings indicate that platelet populations contain discrete secreting and non-secreting cells under the tested conditions, and that the proportion of secreting cells and the magnitude of secretion per cell are tuneable by agonist dose.
A key observation was the presence of a primed platelet state. Platelets classified as primed exhibited elevated responses to agonists compared with non-primed platelets: both the amount of ADP secreted per responding platelet and the fraction of platelets that secreted were increased. Notably, DASA detected ADP secretion from primed platelets even in the absence of added agonists, indicating baseline heightened secretory activity in this state. The authors describe three functional states observed by DASA—primed, active and hyper-active—based on tuneable secretion signatures, though detailed quantitative thresholds and criteria for these categories were not provided in the abstract.
The study reports that primed platelets yielding measurable ADP secretion in DASA were not detected as primed by conventional flow cytometry assays targeting secretion or activation markers CD63 and CD62P. This suggests that DASA provides a functional readout of ADP release that can reveal activation phenotypes not captured by surface-marker–based flow cytometry endpoints.
In vitro exposure of platelets to antiplatelet agents reduced ADP secretion responses measured by DASA. Specifically, the authors report that aspirin and the P2Y12 antagonist ticagrelor decreased ADP secretion responses to agonists. The abstract does not provide concentrations, exposure times, or quantitative effect sizes; those methodological and numerical details are not reported in the source abstract.
In a preliminary clinical study, the authors observed that some patients’ platelets displayed a priming-like ADP secretion signature by DASA. On this basis, they suggest that such a signature might indicate patients who could benefit from treatment with P2Y12 inhibitors. The abstract frames this as preliminary and does not supply cohort size, patient selection criteria, clinical endpoints, or outcome data; those details were not reported in the provided source material.
DASA offers a novel single-cell functional assay to assess platelet reactivity via direct measurement of extracellular ADP release. Strengths highlighted in the abstract include the ability to detect dose-dependent responses, to resolve digital heterogeneity among platelets, and to reveal a primed secretion phenotype not apparent by standard flow cytometry markers. Limitations apparent from the available source text include the absence of peer review (preprint status) and the lack of detailed methods, quantitative thresholds for primed/active/hyper-active states, and full clinical study parameters in the abstract. The authors propose that DASA holds promise for assessing thrombotic tendency and for informing personalised antiplatelet therapy, but further validation, detailed methodological reporting, larger clinical studies and peer review would be required before clinical implementation.